Probiotix Health PLC - Unaudited Interim Results to 30 June 2026
ProBiotix Health plc
("ProBiotix" or the "Company")
Unaudited Interim Results to
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to
Key Financial Highlights
· Gross revenue +53% to
· Gross profit +66% to
· EBITDA profit
· Strong cash balance of
*Excluding share-based payments
Operational Highlights
· Five new partnerships established
· Significant growth of existing customer base
· Strong growth in
· Repositioned US strategy for stronger market penetration in 2027
· Recruitment for clinical study to investigate potential impact of LPLDL® in prediabetes and diabetes
We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering, expanding sales to include third party distribution and a broadened product positioning to offer LPLDL® beyond cholesterol health."
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
|
|
|
|
|
|
|
|
AlbR Capital Limited Aquis Corporate Adviser and Broker |
Tel: 020 7469 0930 |
|
|
|
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the
Notes to Editors:
ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
Chief Executive Officer's overview
The momentum in the business has continued in the first half of 2026, with record revenue growth and a pleasing increase in our gross margin. Moreover, our stated strategy to increase market awareness and boost market penetration, has led to a significant expansion of the customer base.
The Company has continued to expand its global footprint, with the APAC region again proving a particularly strong market. Our partnership with Kemin continues to develop, leading to increasing demand in
Revenue for the first six months of 2026 reached a record
The Board and Management are pleased with the performance achieved in the first half of the year, as it provides further evidence of the success of our strategy.
Strategic Outlook
As a life sciences company with a strategic focus on probiotics and the human microbiome, there remains a significant market opportunity to continue our expansion. ProBiotix operates in the dietary supplement prevention segment, a market which is being driven by the consumer trend of healthy ageing, cardiometabolic health and probiotics.
The strategy continues to target partnerships with scientifically driven dietary supplement suppliers, consumer health and Over the Counter (OTC) companies globally. We continue to provide private label as well as turnkey probiotic dietary supplements to target preventative cardiometabolic health and healthy ageing. The patented LPLDL® continues to be our flagship probiotic strain, developed specifically to support cardiometabolic health.
Results
The Group has delivered a solid trading result during the period, with revenue increasing 53% to
Importantly, the Group has achieved a swing to an EBITDA profit (excluding share-based payments) for the period of
The Group ended the period with a cash and cash equivalents of
Outlook
The active customer base has grown by more than 15% during this period which reflects the growing demand for effective science-backed preventive cardiometabolic supplement products.
We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering expanding sales to include third party distribution, and a broadened product positioning to offer LPLDL® beyond cholesterol health.
The Board and wider management team remain fully committed to delivering the growth strategy we have articulated. We would like to thank all our shareholders and wider stakeholders for their support, and view the future with confidence.
Consolidated Statement of Comprehensive Income
For the 6 months to
|
|
|
|
6 months to 30 June 2026 Unaudited |
6 months to 30 June 2025 Unaudited |
Year ended 31 December 2025 Audited |
|
Continuing operations |
|
|
£'000 |
£'000 |
£'000 |
|
|
|
|
|
|
|
|
Revenue |
3 |
|
2,059 |
1,344 |
2,732 |
|
|
|
|
|
|
|
|
Cost of sales |
|
|
(814) |
(596) |
(1,250) |
|
|
|
|
─────── |
─────── |
─────── |
|
Gross Profit |
|
|
1,245 |
748 |
1,482 |
|
|
|
|
|
|
|
|
Share based payments |
|
|
(46) |
(16) |
(753) |
|
Depreciation and amortisation |
|
|
(26) |
(25) |
(54) |
|
Other administrative costs |
|
|
(1,094) |
(860) |
(1,910) |
|
|
|
|
|
|
|
|
|
|
|
─────── |
─────── |
─────── |
|
Total administrative expenses |
|
|
(1,166) |
(901) |
(2,717) |
|
|
|
|
─────── |
─────── |
─────── |
|
Operating profit/(loss) |
|
|
79 |
(153) |
(1,235) |
|
|
|
|
|
|
|
|
Finance income / (costs) |
|
|
- |
- |
- |
|
|
|
|
─────── |
─────── |
─────── |
|
Profit/(Loss) before Income tax |
|
|
79 |
(153) |
(1,235) |
|
|
|
|
|
|
|
|
Income tax |
|
|
7 |
3 |
2 |
|
|
|
|
─────── |
─────── |
─────── |
|
Profit/(Loss) for the period |
|
|
86 |
(150) |
(1,233) |
|
|
|
|
|
|
|
|
Other Comprehensive Income |
|
|
- |
- |
- |
|
|
|
|
─────── |
─────── |
─────── |
|
Total comprehensive income for the period |
|
|
86
|
(150) |
(1,233) |
|
|
|
|
═══════ |
═══════ |
═══════ |
|
|
|
|
|
|
|
|
Total comprehensive income attributable to the owners of the Group |
|
|
86 |
(150)
|
(1,233)
|
|
|
|
|
═══════ |
═══════ |
═══════ |
|
|
|
|
86 |
(150) |
(1,233) |
|
Earnings/(loss) per share |
|
|
|
|
|
|
Basic & Diluted - pence |
4 |
|
0.05p |
(0.09)p |
(0.78)p |
|
|
|
|
═══════ |
═══════ |
═══════ |
Consolidated Statement of Financial Position
As at
|
|
Notes |
As at 30 June 2026 Unaudited |
As at 30 June 2025 Unaudited |
As at 31 December 2025 Audited |
|
ASSETS |
|
£'000 |
£'000 |
£'000 |
|
Non-current assets |
|
|
|
|
|
Intangibles |
|
161 |
211 |
186 |
|
Property plant and equipment |
|
6 |
7 |
5 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
167 |
218 |
191 |
|
|
|
─────── |
─────── |
─────── |
|
CURRENT ASSETS |
|
|
|
|
|
Inventories |
|
- |
17 |
- |
|
Trade and other receivables |
|
560 |
846 |
351 |
|
Cash and cash equivalents |
|
1,244 |
1,299 |
1,266 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
1,804 |
2,162 |
1,617 |
|
|
|
─────── |
─────── |
─────── |
|
TOTAL ASSETS |
|
1,971 |
2,380 |
1,808 |
|
|
|
═══════ |
═══════ |
═══════ |
|
EQUITY |
|
|
|
|
|
Shareholders' Equity |
|
|
|
|
|
Called up share capital |
5 |
79 |
79 |
79 |
|
Group reorganisation reserve |
|
(945) |
(945) |
(945) |
|
Share premium |
|
4,534 |
4,534 |
4,534 |
|
Share based payment reserve |
|
840 |
57 |
794 |
|
Retained Earnings |
|
(2,933) |
(1,936) |
(3,019) |
|
|
|
|
|
|
|
|
|
─────── |
─────── |
─────── |
|
Total Equity |
|
1,575 |
1,789 |
1,443 |
|
|
|
─────── |
─────── |
─────── |
|
LIABILITIES |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
356 |
538 |
318 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
356 |
538 |
318 |
|
|
|
─────── |
─────── |
─────── |
|
Non - current liabilities |
|
|
|
|
|
Deferred tax liability |
|
40 |
53 |
47 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
40 |
53 |
47 |
|
|
|
─────── |
─────── |
─────── |
|
TOTAL LIABILITIES |
|
396 |
591 |
365 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
|
|
|
|
TOTAL EQUITY AND LIABILITIES |
|
1,971 |
2,380 |
1,808 |
|
|
|
|
|
|
|
|
|
═══════ |
═══════ |
═══════ |
Consolidated Statement of Changes in Equity
For six months to
|
|
Called up Share Capital |
Share premium |
Group Reorganisation reserve |
Share-based Payment reserve |
Retained Earnings |
Total Equity |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at |
79 |
4,534 |
(945) |
41 |
(1,786) |
1,923 |
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(150) |
(150) |
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
16 |
- |
16 |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at |
79 |
4,534 |
(945) |
57 |
(1,936) |
1,789 |
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(1,083) |
(1,083) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
737 |
- |
737 |
|
|
|
|
|
|
|
|
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at |
79 |
4,534 |
(945) |
794 |
(3,019) |
1,443 |
|
|
|
|
|
|
|
|
|
Profit for the period |
- |
- |
- |
- |
86 |
86 |
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
46 |
- |
46 |
|
|
|
|
|
|
|
|
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at |
79 |
4,534 |
(945) |
840 |
(2,933) |
1,575 |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
Consolidated Statement of Cash Flows
For the six months to
|
|
Notes |
6 months to 30 June 2026 Unaudited |
Period to 30 June 2025 Unaudited |
Year ended 31 December 2025 Audited |
|
|
|
£'000 |
£'000 |
£'000 |
|
Reconciliation of loss before income tax to cash outflow from operations |
|
|
|
|
|
Operating profit/(loss) |
|
79 |
(153) |
(1,235) |
|
Decrease/ (Increase) in inventories |
|
- |
14 |
31 |
|
(Increase)/decrease in trade and other receivables |
|
(208) |
(589) |
(94) |
|
(Decrease)/increase in trade and other payables |
|
38 |
343 |
123 |
|
Share based payments |
|
46 |
16 |
753 |
|
Depreciation and amortisation |
|
26 |
25 |
54 |
|
Net Fx Difference |
|
|
(3) |
- |
|
|
|
────── |
────── |
────── |
|
Net cash outflow from operations |
|
(19) |
(347) |
(368) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax received |
|
- |
- |
- |
|
|
|
────── |
────── |
────── |
|
Net cash (outflow)/inflow from operating activities |
|
(19) |
(347) |
(368) |
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
|
|
|
Purchase of intangible assets |
|
(3) |
- |
(12) |
|
|
|
────── |
────── |
────── |
|
Net cash (outflow)/inflow from investing activities |
|
(3) |
- |
(12) |
|
|
|
────── |
────── |
────── |
|
Cash flows from financing activities |
|
|
|
|
|
Share issue net of costs |
|
- |
- |
- |
|
|
|
────── |
────── |
────── |
|
Net cash inflow from financing activities |
|
- |
- |
- |
|
|
|
────── |
────── |
────── |
|
|
|
|
|
|
|
Increase/(decrease) in cash and equivalents |
|
(22) |
(347) |
(380) |
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period |
|
1,266 |
1,646 |
1,646 |
|
|
|
────── |
────── |
────── |
|
Cash and cash equivalents at end of period |
|
1,244 |
1,299 |
1,266 |
|
|
|
══════ |
══════ |
══════ |
Notes to the results
For the six months to
1. General Information
ProBiotix Health plc is a company incorporated and domiciled in
The financial information set out in this report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Group's statutory financial statements for the period ended
Copies of the annual statutory accounts and the Half Yearly report can be found on the Company's website https://probiotixhealth-ir.com/financials/latest-results
2. Basis of preparation and significant accounting policies
This report has been prepared using the historical cost convention, on a going concern basis and in accordance with
The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the accounting policies and making any estimates. Changes in assumptions may have a significant impact on the financial statements in the period the assumptions changed. The Board of Directors believe that the underlying assumptions are appropriate and that the financial statements are fairly presented. The Board of Directors believes that there are no areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, and therefore, these financial statements have limited disclosures.
3. Segmental Reporting
In the opinion of the directors, the Group has one class of business, in four geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. The Group sells into three highly interconnected markets, all costs assets and liabilities are derived from locations in the
Revenue analysed by geographical market
|
|
6 months 30 June 2026 |
6 months 30 June 2025 |
Year to 31 December 2025 |
|
|
£'000 |
£'000 |
£'000 |
|
|
- |
34 |
61 |
|
US |
1,048 |
760 |
1,810 |
|
|
276 |
51 |
- |
|
ROW |
735 |
499 |
861 |
|
|
────── |
────── |
────── |
|
|
2,059 |
1,344 |
2,732 |
|
|
══════ |
══════ |
══════ |
During the reporting period one customer represented
4. Earnings per Share
Basic earnings per share is calculated by dividing the earnings attributable shareholders by the weighted average number of ordinary shares outstanding during the period.
Reconciliations are set out below:
|
|
6 Months to Unaudited |
6 Months to Unaudited |
Year to Audited |
|
|
£ |
£ |
£ |
|
Basic & Diluted |
|
|
|
|
|
|
|
|
|
Earnings attributable to ordinary shareholders |
86,000 |
(150,000) |
(1,233,000) |
|
|
|
|
|
|
Weighted average number of shares |
158,166,666 |
158,166,666 |
158,166,666 |
|
|
|
|
|
|
Earnings /(Loss) per-share - pence |
0.05p |
(0.09)p |
(0.78)p |
|
|
═════ |
═════ |
═════ |
|
|
|
|
|
As at
5. Share Capital
Issued share capital comprises:
|
Shares in issue |
|
|
|
|
|
Opening balance |
158,166,666 |
|
|
|
|
|
────── |
|
Closing balance at |
158,166,666 |
|
|
══════ |
|
Share capital |
£'000 |
|
|
|
|
Opening balance |
79 |
|
|
|
|
|
────── |
|
Closing balance at |
79 |
|
|
══════ |
6. Post balance sheet events
There are no post balance sheet events.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE